Hormone Therapy for Lung Cancer Peekskill NY

Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found. The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.

Local Companies

Ossining Correctional Fac Hosp
914-941-0108
354 Hunter Street
Ossining, NY
Summit Park Hospital
845-364-2700
50 Sanatorium Road
Pomona, NY
Four Winds Hospital
914-763-8151
800 Cross River Road
Katonah, NY
Northern Westchester Hospital
914-666-1200
400 East Main Street
Mount Kisco, NY
St Luke'S Cornwall Hospital
845-561-4400
70 Dubois Street
Newburgh, NY
Phelps Memorial Hospital Cntr
914-366-3000
701 North Broadway
Sleepy Hollow, NY
Va Hudson Vly Hlth Care System
914-737-4400
2094 Albany Post Road
Montrose, NY
Rockland Children'S Psych Ctr
845-359-7400
599 Convent Road
Orangeburg, NY
Arms Acres
845-225-3400
75 SEminary Hill Road
Carmel, NY
Good Samaritan Hospital
845-368-5000
255 Lafayette Avenue
Suffern, NY
Data Provided by:
  

Provided By:

SATURDAY, Sept. 19 (HealthDay News) -- Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found.

The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.

After eight years, 73 women taking the hormone therapy and 40 women in the placebo group had died of lung cancer. That meant, according to the researchers, that women who took the drug were 71 percent more likely to die from the disease.

The study also found that women taking the hormone therapy were 28 percent more likely to be diagnosed with lung cancer, although the study noted that the finding was not statistically significant.

"Treatment with estrogen plus progestin in postmenopausal women ... increased the number of deaths from lung cancer, in particular deaths from non-small-cell lung cancer," concluded Rowan Chlebowski, of the Los Angeles Biomedical Research Institute at Harbour-UCLA Medical Center, and his colleagues.

The researchers urged that the findings "be incorporated into risk-benefit discussions with women considering combined hormone therapy, especially those with a high risk of lung cancer ... such as current smokers or long-term past smokers."

Dr. Apar Kishor Ganti, from the University of Nebraska Medical Center in Omaha, wrote in an accompanying editorial that "because the optimum safe duration of hormone-replacement therapy in terms of lung cancer survival is unclear, such therapy should probably be avoided in women at a high risk of developing lung cancer, especially those with a history of smoking."

In fact, Ganti questioned whether hormone therapy should be used at all.

"These results, along with the findings showing no protection against coronary heart disease, seriously question whether hormone-replacement therapy has any role in medicine today," he wrote. "It is difficult to presume that the benefits of routine use of such therapy for menopausal symptoms outweigh the increased risks of mortality, especially in the absence of improvement in the quality of life."

The study, which appears online and in an upcoming print issue of The Lancet, was released Sept. 19 to coincide with the European Cancer Organization meeting.

More information

The U.S. National Institute on Aging has more on hormones and menopause.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Drug Combo Proves Powerful Against Lung Cancer Peekskill NY
A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.
- Breast Cancer Treatment Peekskill NY
- Hormone Therapy for Early Prostate Cancer Peekskill NY
- Delayed Prostate Cancer Therapy Peekskill NY
- Hormone Therapy Peekskill NY
- Head and Neck Cancer Treatment Peekskill NY
- Hormone Therapy for Prostate Cancer Peekskill NY
- Hormone Therapy for Breast Cancer Peekskill NY
- Menopausal Hormone Therapy Peekskill NY